Latest From Ipsen
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
Ipsen’s tyrosine kinase inhibitor, Cabometyx, is the first product to be registered under a new Australian procedure that aims to get prescription drugs to market faster by using medicine assessments already conducted by comparable overseas regulators.
Two successful Phase III studies of Inlyta in combination with two distinct immunotherapies, including its own, Merck KGaA-partnered Bavencio, puts Pfizer in a very strong position in the advanced kidney cancer market.
2019 looks set to be a transformative year for Ipsen, with a pivotal clinical trial readout expected for combination Cabometyx in frontline kidney and liver cancer, and a series of deals promised by the company to investors looking for reassurance over long-term growth. CEO David Meek spoke to Scrip.
- OTC, Consumer
- Specialty Pharmaceuticals
- Therapeutic Areas
- Gynecological, Urological
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Beaufour Ipsen
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Senior Management
David Meek, CEO
Aymeric Le Chatelier, EVP, Fin. & CFO
Alexandre Lebeaut, MD, EVP, R&D & CSO
Ivana Magovcevic-Liebisch, EVP, CBO
- Contact Info
Phone: (33) 1 58 33 50 00
65 quai George Gorse
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.